SCHEMBL2614968

SCHEMBL2614968

Cc1ncc(Cl)cc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2111945 0.79
SCHEMBL2112692 0.79
SCHEMBL14934167 0.77 MKNK1 (0.41)
SCHEMBL9948527 0.75
SCHEMBL10153693 0.75
SCHEMBL31627336 0.75
SCHEMBL2067135 0.75
SCHEMBL13736309 0.75
SCHEMBL20544773 0.75
SCHEMBL19555715 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4393914-A1 IMIDAZOCYCLIC COMPOUND AND APPLICATION THEREOF Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. (CN) 2024-07-03 EP disclosed
WO-2024074651-A1 SARS-COV-2 MPRO INHIBITORS AND USES THEREOF HEPTARES THERAPEUTICS LIMITED (GB) 2024-04-11 WO disclosed
EP-4273147-A1 SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES Bayer Aktiengesellschaft (DE) 2023-11-08 EP disclosed
US-20230286918-A1 MANUFACTURING PROCESS FOR 3,5-DICHLOROPICOLINONITRILE FOR SYNTHESIS OF VADADUSTAT AKEBIA THERAPEUTICS, INC. (US) 2023-09-14 US disclosed
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring CAPULUS THERAPEUTICS, LLC (US) 2023-08-08 US disclosed
US-20230151002-A1 6-5 FUSED RINGS AS C5a INHIBITORS CHEMOCENTRYX, INC. 2023-05-18 US disclosed
US-20230151002-A1 6-5 FUSED RINGS AS C5a INHIBITORS CHEMOCENTRYX, INC. 2023-05-18 US disclosed
WO-2023014908-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. (US) 2023-02-09 WO disclosed
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
EP-3247712-B1 PESTICIDALLY ACTIVE POLYCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS SYNGENTA PARTICIPATIONS AG (CH) 2022-04-20 EP disclosed
US-20080027110-A1 Indolyl-3-glyoxylic acid derivatives having antitumor action ASTA MEDICA AKTIENGESELLSCHAFT 2008-01-31 US disclosed
WO-2008010061-A2 3-AZABICYCLO [3.1.0] HEXANE VANILLOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION GLENMARK PHARMACEUTICALS S.A. (US) 2008-01-24 WO disclosed
WO-2007089034-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed
US-20070149557-A1 CXCR3 antagonists AMGEN INC. (US) 2007-06-28 US disclosed
US-6716987-B1 PHOSPHODIESTERASE IV INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-04-06 US disclosed
EP-1029860-B1 BENZOFURAN DERIVATIVES KYOWA HAKKO KOGYO KK (JP) 2003-04-16 EP disclosed
US-6514996-B2 Derivatives of benzofuran or benzodioxole KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-02-04 US disclosed
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-09-12 US disclosed
US-6395738-B1 ANTIINFLAMMATORY, ANTIALLERGENS KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-05-28 US disclosed
EP-1029860-A1 BENZOFURAN DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2000-08-23 EP disclosed